Xavier Leroy
YOU?
Author Swipe
View article: A Lazy, Concurrent Convertibility Checker
A Lazy, Concurrent Convertibility Checker Open
Convertibility checking - determining whether two lambda-terms are equal up to reductions - is a crucial component of proof assistants and dependently-typed languages. Practical implementations often use heuristics to quickly conclude that…
View article: Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome
Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome Open
Objectives To determine if quantifying Gleason pattern 4 (GP4) is superior to Grade Group (GG) in predicting any and distant metastatic recurrence after radical prostatectomy (RP) for prostate cancer, and compare various GP4 quantification…
View article: Long-term oncological outcomes of active surveillance for low-risk prostate cancer diagnosed during the MRI era
Long-term oncological outcomes of active surveillance for low-risk prostate cancer diagnosed during the MRI era Open
Level 2.
View article: Practice patterns and survival outcomes for muscle-invasive bladder cancer: real-life experience in a general population setting
Practice patterns and survival outcomes for muscle-invasive bladder cancer: real-life experience in a general population setting Open
Bladder cancer (BC) is a common malignancy in Europe and North America. Among BCs, muscle-invasive BCs (MIBCs) are distinguished, as they require aggressive treatment due to their spreading potential and poor prognosis. Despite its clinica…
View article: Robot Partial Prostatectomy for Anterior Cancer: Long-term Functional and Oncological Outcomes at 7 Years
Robot Partial Prostatectomy for Anterior Cancer: Long-term Functional and Oncological Outcomes at 7 Years Open
In this report, we looked at outcomes for infrequent cases of anterior prostate cancer treated with anterior partial prostatectomy, an uncommon surgical procedure as an alternative to in situ focal ablation therapy, to better preserve func…
View article: EGFR signaling and pharmacology in oncology revealed with innovative BRET-based biosensors
EGFR signaling and pharmacology in oncology revealed with innovative BRET-based biosensors Open
Dysregulation of receptor tyrosine kinases (RTKs) is associated with the development of many cancers. Intrinsic and acquired mutations of RTKs modify receptor signaling contributing to drug resistance in clinical settings. We present enhan…
View article: Supplementary Figure Legends 1-3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Supplementary Figure Legends 1-3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
Supplementary Figure Legends 1-3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
View article: Supplementary Table 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Supplementary Table 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
Supplementary Table 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
View article: Supplementary Figure 3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Supplementary Figure 3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
Supplementary Figure 3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
View article: Supplementary Figure 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Supplementary Figure 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
Supplementary Figure 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
View article: Supplementary Figure 2 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Supplementary Figure 2 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
Supplementary Figure 2 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
View article: Supplementary Figure 3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Supplementary Figure 3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
Supplementary Figure 3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
View article: Supplementary Table 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Supplementary Table 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
Supplementary Table 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
View article: Supplementary Table 1, Figures 1 - 8 from PLA2R1 Mediates Tumor Suppression by Activating JAK2
Supplementary Table 1, Figures 1 - 8 from PLA2R1 Mediates Tumor Suppression by Activating JAK2 Open
PDF file - 326K, Supplementary Figure 1: The knockdown of PLA2R1 favors OIS escape. Supplementary Figure 2: The knockdown of PLA2R1 favors transformation. Supplementary Figure 3: The knockdown of PLA2R1 favors OIS escape in human normal ke…
View article: Supplementary Figure 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Supplementary Figure 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
Supplementary Figure 1 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
View article: Supplementary Figure Legends 1-3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Supplementary Figure Legends 1-3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
Supplementary Figure Legends 1-3 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
View article: Data from PLA2R1 Mediates Tumor Suppression by Activating JAK2
Data from PLA2R1 Mediates Tumor Suppression by Activating JAK2 Open
Little is known about the physiological role of the phospholipase A2 receptor (PLA2R1). PLA2R1 has been described as regulating the replicative senescence, a telomerase-dependent proliferation arrest. The downstream PLA2R1 signaling and it…
View article: Supplementary Figure 2 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Supplementary Figure 2 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
Supplementary Figure 2 from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
View article: Data from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Data from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
The hypoxia inducible factor (HIF) signaling pathway is known as the main renal carcinogenetic pathway. MUC1, an O-glycoprotein membrane-bound mucin, is overexpressed in clear renal cell carcinomas (cRCC) with correlation to two major prog…
View article: Data from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Data from MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression Open
The hypoxia inducible factor (HIF) signaling pathway is known as the main renal carcinogenetic pathway. MUC1, an O-glycoprotein membrane-bound mucin, is overexpressed in clear renal cell carcinomas (cRCC) with correlation to two major prog…
View article: Supplementary Table 1, Figures 1 - 8 from PLA2R1 Mediates Tumor Suppression by Activating JAK2
Supplementary Table 1, Figures 1 - 8 from PLA2R1 Mediates Tumor Suppression by Activating JAK2 Open
PDF file - 326K, Supplementary Figure 1: The knockdown of PLA2R1 favors OIS escape. Supplementary Figure 2: The knockdown of PLA2R1 favors transformation. Supplementary Figure 3: The knockdown of PLA2R1 favors OIS escape in human normal ke…
View article: Data from PLA2R1 Mediates Tumor Suppression by Activating JAK2
Data from PLA2R1 Mediates Tumor Suppression by Activating JAK2 Open
Little is known about the physiological role of the phospholipase A2 receptor (PLA2R1). PLA2R1 has been described as regulating the replicative senescence, a telomerase-dependent proliferation arrest. The downstream PLA2R1 signaling and it…
View article: 814 DT-9081, a selective EP<sub>4</sub>receptor antagonist which synergizes with immune checkpoint inhibitors to induce complete responses in syngeneic murine cancer models
814 DT-9081, a selective EP<sub>4</sub>receptor antagonist which synergizes with immune checkpoint inhibitors to induce complete responses in syngeneic murine cancer models Open
Background Elevated levels of Prostaglandin E2 (PGE2), an eicosanoid synthesized by the cyclooxygenase-2 (COX-2), exert strong immunosuppressive effects in the tumor microenvironment (TME). COX-2-positive solid tumors have the ability to u…
View article: 1393 Beyond CCR8 key epitopes targeting dynamic CCR8 conformational states and a diversity of monoclonal antibodies to modulate the tumor microenvironment for the treatment of cancers
1393 Beyond CCR8 key epitopes targeting dynamic CCR8 conformational states and a diversity of monoclonal antibodies to modulate the tumor microenvironment for the treatment of cancers Open
Background Chemokine (C-C motif) receptor 8 (CCR8) belongs to the G protein-coupled receptor (GPCR) family. Based on the transcriptional landscape of tumor infiltrating T regulatory cells, it has been found that CCR8 positive tumor infiltr…
View article: Comprehensive study of nine novel cases of <scp><i>TFEB</i></scp>‐amplified renal cell carcinoma: an aggressive tumour with frequent <scp>PDL1</scp> expression
Comprehensive study of nine novel cases of <span><i>TFEB</i></span>‐amplified renal cell carcinoma: an aggressive tumour with frequent <span>PDL1</span> expression Open
Aims First described in 2014, renal cell carcinoma (RCC) with TFEB amplification (6p21) is a rare molecular subgroup whose diagnosis is challenging. The prognosis and therapeutic implications remain unclear. Methods We report here the clin…